Complete Response Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Complete Response clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults

Incomplete Response - Major Depressive Disorder (IR-MDD)
Otsuka Pharmaceutical Development & Commercialization, Inc.18 enrolled1 locationNCT07329621
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma

ESCCPathological Complete ResponseTotal Neoadjuvant Treatment
National Taiwan University Hospital50 enrolled1 locationNCT06764355
Recruiting

Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

Esophageal Squamous Cell CarcinomaPathological Complete ResponseDeep Learning+1 more
Tongji Hospital300 enrolled1 locationNCT07088354
Recruiting
Phase 2

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

ChemotherapyPD-1 InhibitorInduction Therapy+2 more
The First Affiliated Hospital of Xiamen University208 enrolled3 locationsNCT06811844
Recruiting
Not Applicable

RGL-305+ Lymphoma + Exploratory Clinical Study

Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD)
Fudan University12 enrolled1 locationNCT07006012
Recruiting
Not Applicable

Omission of ALND in Breast Cancer Patients With Axillary pCR

Breast CancerAxillary Lymph Node DissectionPathological Complete Response+2 more
The First Affiliated Hospital with Nanjing Medical University92 enrolled1 locationNCT05939830
Recruiting

The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial.

Clinical Complete Response Rate With Negative MRD
Yunnan Cancer Hospital22 enrolled1 locationNCT06477991
Recruiting

The Prognostic Value of the Degree of Pathological Response of Induction Chemotherapy for NPC

Nasopharyngeal CarcinomaTumor MicroenvironmentPathologic Complete Response
Jiangxi Provincial Cancer Hospital300 enrolled1 locationNCT06182657
Recruiting
Not Applicable

Refusal of Breast Surgery in Patients With Breast Cancer With a Clinical Complete Response (cCR) After Neoadjuvant Systemic Therapy and a Confirmed Pathological Complete Response (pCR) Using Vacuum-assisted Biopsy (VAB) and Sentinel Lymph Node Biopsy (SLNB)

Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB
N.N. Petrov National Medical Research Center of Oncology60 enrolled1 locationNCT04293796